您的购物车当前为空
Xanthine oxidase-IN-4 (化合物 19a) 是一种具有口服活性的有效黄嘌呤氧化酶 (XO) 抑制剂,IC50值为0.039 μM,可用于高尿酸血症和痛风的研究。Xanthine oxidase-IN-4 在氧嗪酸钾诱导的高尿酸血症大鼠中表现出降尿酸能力。
Xanthine oxidase-IN-4 (化合物 19a) 是一种具有口服活性的有效黄嘌呤氧化酶 (XO) 抑制剂,IC50值为0.039 μM,可用于高尿酸血症和痛风的研究。Xanthine oxidase-IN-4 在氧嗪酸钾诱导的高尿酸血症大鼠中表现出降尿酸能力。

| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 25 mg | ¥ 10,600 | 6-8周 | |
| 50 mg | ¥ 13,800 | 6-8周 | |
| 100 mg | ¥ 17,500 | 6-8周 |
TargetMol的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。
| 产品描述 | Xanthine oxidase-IN-4 (compound 19a) is an orally active and potent inhibitor of xanthine oxidase(XO) with an IC 50 of 0.039 μM that can be used in the research of hyperuricemia and gout. Xanthine oxidase-IN-4 shows hypouricemic potency in potassium oxonate induced hyperuricemia rats. [1]. |
| 体外活性 | Xanthine oxidase-IN-4 (compound 19a) (1 nM-10 μM, 15 min) exhibits a strong XO inhibitory potency, with an IC 50 of 0.039 μM, and Ki of 0.0037 μM [1]. |
| 体内活性 | Xanthine oxidase-IN-4 (compound 19a) (SD rats, 10 mg/kg, Intragastrically, once) significantly reduces the serum concentration of uric acid [1]. Animal Model: Sprague-Dawley rats (Six weeks, male, 180-200g, six groups) [1] Dosage: 10 mg/kg Administration: Intragastrically, once Result: Significantly reduced the serum concentration of uric acid, with AUC (uric acid, 1-5 h) of 44.3%. |
| 分子量 | 295.3 |
| 分子式 | C15H13N5O2 |
| CAS No. | 2642137-96-8 |
| Smiles | C(#N)C=1C=C(C=2N=C3C(=CN2)C(=O)NN3)C=CC1OC(C)C |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. 实际储存温度请以COA为准 |
对于不同动物的给药剂量换算,您也可以参考 更多